Anti-Inflammatory Effect of Combined Sitagliptin and Vitamin D3 on Cytokines Profile in Patients with Type 2 Diabetes Mellitus
| Autor: | Mohammad Ali Amirzargar, Vida Sheikh, Azadeh Mozayanimonfared, Zohre Zareighane, Iraj Salehi, Mahdi Alahgholi-Hajibehzad, Shiva Borzouei, Alireza Zamani, Morteza Ghasemi, Zahra Telikani |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male 0301 basic medicine Vitamin medicine.medical_specialty medicine.drug_class medicine.medical_treatment Immunology Anti-Inflammatory Agents Enzyme-Linked Immunosorbent Assay Gastroenterology Anti-inflammatory Proinflammatory cytokine Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interferon Virology Internal medicine medicine Humans Diabetic Nephropathies In patient Cholecalciferol business.industry Sitagliptin Phosphate Type 2 Diabetes Mellitus Cell Biology Middle Aged Drug Combinations 030104 developmental biology Cytokine Diabetes Mellitus Type 2 chemistry 030220 oncology & carcinogenesis Sitagliptin Cytokines Female business medicine.drug |
| Zdroj: | Journal of Interferon & Cytokine Research. 39:293-301 |
| ISSN: | 1557-7465 1079-9907 |
| DOI: | 10.1089/jir.2018.0144 |
| Popis: | Studies indicated that imbalance of proinflammatory and anti-inflammatory cytokines may contribute to development of type 2 diabetes mellitus (T2DM). We hypothesized that sitagliptin and VitD3 may exert more anti-inflammatory effects on the regulation of cytokine balance in T2DM. Nonnephropathic and nephropathic T2DM patients were divided into the subgroups, based on treatments. The effect of 8 months sitagliptin, alone or together with 2 months of VitD3, on serum IFN-γ, IL-4, IL-17, IL-6, IL-21, TGF-β, and IL-37 levels was determined using enzyme-linked immunosorbent assay. Increased levels of interferon (IFN)-γ and IL-17 in untreated (without sitagliptin and VitD3) nephropathic and nonnephropathic patients and decreased levels of IL-37 in untreated nephropathic patients were observed compared with healthy controls. Treatment with sitagliptin plus VitD3 reduced the levels of IFN-γ and IL-17 in both nonnephropathic and nephropathic patients compared with untreated patients. The level of IL-37 was enhanced in patients treated with sitagliptin or sitagliptin plus VitD3, compared with untreated patients. Sitagliptin plus VitD3 treatment increased the levels of IL-4 in nonnephropathic patients. These findings indicated that the sitagliptin plus VitD3 was more effective to reduce the increased proinflammatory IFN-γ and IL-17 cytokines in T2DM patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|